LuciCapma contains capmatinib, a targeted therapy used in
the treatment of certain types of non-small cell lung cancer (NSCLC). It is
specifically prescribed for patients whose cancer is associated with MET gene
alterations. This medication is used globally in oncology practice for
personalized cancer treatment.
Active Ingredient
Capmatinib is a MET inhibitor that targets abnormal
signaling pathways responsible for cancer cell growth. It blocks the MET
receptor tyrosine kinase, helping to slow tumor progression.
Uses of LuciCapma
• Treatment of metastatic non-small cell lung cancer
• MET exon 14 skipping mutation-positive NSCLC
How LuciCapma Works
Capmatinib inhibits MET receptor signaling pathways, which
are often overactive in certain lung cancers. By blocking this pathway, it
reduces cancer cell growth and spread.
How to Use LuciCapma
• Take as prescribed by a healthcare professional
• Usually taken orally with or without food
• Follow dosage instructions carefully
Possible Side Effects
• Nausea
• Fatigue
• Peripheral edema
• Vomiting
Precautions
• Monitor liver function
• Avoid during pregnancy
• Inform doctor about all medications
Safety Information
Use only under medical supervision. Regular monitoring is
required to assess response and side effects.
Storage
• Store at room temperature
• Protect from moisture and sunlight
• Keep out of reach of children